Results 221 to 230 of about 344,975 (368)

MINDSETS: Multi-omics Integration with Neuroimaging for Dementia Subtyping and Effective Temporal Study. [PDF]

Sci Rep
Hassan S, Akaila D, Arjemandi M, Papineni V, Yaqub M.   +4 more
europepmc   +1 more source

Accelerated Biological Aging and Longitudinal Progression of Cardiometabolic Disease, Subsequent Dementia, and Death: A Multistate Analysis. [PDF]

Eur J Neurol
ABSTRACT Background The role of biological age (BA) acceleration in longitudinal disease progression from health to cardiometabolic disease (CMD), then to post‐CMD dementia (including vascular dementia (VaD) and Alzheimer's disease (AD)), and finally to death remains unclear.
Zhang N, Zuo H, Cai J, Xiang Y, Zhang Y, Zhang H, Hu Y, Xu H, Xiao X, Zhao X.   +9 more
europepmc   +2 more sources

CLINICAL DECISION SUPPORT SYSTEM FOR OPTIMAL VAD WEANING [PDF]

, 2005
L C Santelices, Marek J. Drużdżel, Richard Schaub, Bronwyn E. Uber, Robert L. Kormos, James F. Antaki   +5 more
openalex   +1 more source

Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor

Molecular Cancer Therapeutics, 2009
L. Moretti, K. W. Kim, D. K. Jung, C. Willey, B. Lu   +4 more
semanticscholar   +1 more source

Dipyridamole Acts as Clinical Ferroptosis Inhibitor to Prevent from Tissue Injury

Advanced Science, Volume 12, Issue 23, June 20, 2025.
Dipyridamole acts as a clinically used compound to suppress ferroptosis. Dipyridamole down‐regulates the expression of RNF126, which is an E3 ligase to ubiquitinate SLC7A11 for proteasome degradation. The deficiency of SLC7A11 largely abolishes the protective role of dipyridamole both in vitro and in vivo.
Xiao Zhuang, Shuang Shi, Shuo Liu, Yaqiong Jiao, Bin Huang, Yinghong Yang, Li Yang, Xinquan Yang, Hui Wang, Chunhui Liang, Dandan Song, Huaxiang Yu, Dan Zou, Qi Sun, Shu Yang, Chengqian Yin, Jian Li, Yiming Liu, Junxia Min, Fudi Wang, Yong Nian, Lutao Du, Bo Chu   +22 more
wiley   +1 more source

ALTERED AORTIC HEMODYNAMICS WITH CONTINUOUS FLOW VAD SUPPORT

, 2002
Kenneth N. Litwak, Shińichiro Kihara, Zhongjun J. Wu   +2 more
openalex   +1 more source

Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers

Alzheimer's &Dementia, Volume 21, Issue 6, June 2025.
Abstract Individuals with Down syndrome (DS) have a genetically determined form of Alzheimer's disease (AD) due to the amyloid precursor protein (APP) gene dose effect. Nearly all individuals with DS develop AD pathology by age 40. Although dementia is rare before this age, its incidence rises sharply thereafter.
Isabel Barroeta, Laura Videla, María Carmona‐Iragui, Juan Fortea, Michael S. Rafii   +4 more
wiley   +1 more source

Effectiveness of Vascular Catheter Removal Versus Retention in Non-ICU Patients with CRBSI or CABSI in Retrospective, Single-Center Study. [PDF]

Microorganisms
De Capitani G, Colaneri M, Conflitti C, Borgonovo F, Galli L, Scaglione G, Genovese C, Fattore R, Schiavini M, Caloni B, Zizzo D, Busatto N, Gidaro A, Taino A, Calloni M, Casella F, Bartoli A, Cogliati C, Palomba E, Antinori S, Gori A, Foschi A.   +21 more
europepmc   +1 more source

Notat vedr. energisystemer og brændeovne [PDF]

, 2008
Mathiesen, Brian Vad
core  

Influence of ethnicity on the diagnostic accuracy of plasma p‐tau217 for the identification of Alzheimer's disease: A consecutive mixed memory clinic cohort study

Alzheimer's &Dementia, Volume 21, Issue 6, June 2025.
Abstract INTRODUCTION Blood‐based biomarkers have demonstrated high accuracy for identifying Alzheimer's disease (AD) pathology. However, the lack of representative cohorts creates a knowledge gap regarding their real‐world applicability. We examined the influence of ethnicity on the diagnostic accuracy of plasma tau phosphorylated at threonine 217 (p ...
Daniel Kjaergaard, T. Rune Nielsen, Erik Stomrud, Sebastian Palmqvist, Divya Bali, Anna Orduña Dolado, Shorena Janelidze, Oskar Hansson, Gunhild Waldemar, Anja Hviid Simonsen   +9 more
wiley   +1 more source